Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies

Thermo Fisher Scientific, the world leader in serving science, and Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage cell therapy company engineering advanced chimeric antigen receptor (CAR)-T cell therapies for solid tumors, today announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments.

Related Keywords

United States ,Ken Drazan ,Kristin Blake ,Unity Lab Services ,Fisher Scientific ,Thermo Fisher Scientific Inc ,Cell Therapy Collaboration Program ,Thermo Fisher ,Arsenal Biosciences Inc ,Our Mission ,Arsenal Biosciences ,Cell Therapy Systems ,Electroporation System ,Counterflow Centrifugation ,Betty Woo ,Thermo Scientific ,Applied Biosystems ,Media Contact ,Thermo Fisher Scientific ,Clinical Manufacturing ,Utologoust Cell Therapies ,Rsenalbio ,Chimeric Antigen Receptor ,Solid Tumors ,Strategic Collaboration ,Manufacturing Processes ,Cancer Treatments ,Rogrammable Autologoust Cells ,Ntegrated Circuitt Cell ,Ct Therapy ,Platinum Resistant Ovarian Cancer ,Tibco ,Its ,Lenon ,Gmp ,